問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2017-02-17 - 2020-12-17
Condition/Disease
Crohn’s Disease
Test Drug
Filgotinib
Participate Sites13Sites
Recruiting8Sites
Terminated3Sites
Division of General Internal Medicine
未分科
Active Crohn’s Disease
Filgotinib, 100 mg and 200 mg per tablet
Participate Sites14Sites
Recruiting9Sites
2018-06-29 - 2022-06-30
Systemic Lupus Erythematosus
BMS-986165
Participate Sites8Sites
2022-01-01 - 2025-12-31
Participate Sites2Sites
Recruiting2Sites
2021-04-01 - 2022-07-31
facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC)
Rapamycin
Participate Sites1Sites
Recruiting1Sites
2013-01-01 - 2022-12-31
Participate Sites5Sites
Not yet recruiting2Sites
Recruiting3Sites
2020-08-01 - 2023-11-23
Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
ENTRECTINIB (RXDX-101)
2021-03-17 - 2025-06-15
2021-09-01 - 2023-07-31
Prurigo Nodularis/Pruritis
KPL-716/ vixarelimab
Participate Sites4Sites
Recruiting4Sites
2020-12-01 - 2022-03-22
全部
